AstraZeneca opens $360m drug manufacturing facility in Dublin as Ireland bets on pharma resilience
AstraZeneca has inaugurated a $360 million active pharmaceutical ingredient manufacturing facility in Dublin, in a move that reinforces Ireland’s position as a critical node in the Anglo-Swedish drugmaker’s global supply network. The facility opening comes at a moment of heightened uncertainty over transatlantic trade.
Pam Cheng, AstraZeneca’s executive vice president for global operations, said the facility was “an innovative and unique asset in our global operations network” that would play “a key role in the development and launch of our new medicines across our oncology portfolio and beyond.”
Life sciences investment
The plant, located at the Alexion Campus in College Park, Dublin, will produce small molecule APIs for late-stage development and early commercial supply, and is designed to serve the company’s oncology pipeline and broader medicines portfolio.
The facility, developed with the backing of state investment agency IDA Ireland, is expected to create…
